Tequin (gatifloxacin), one of a group of broad-spectrum antibiotics used to treat lung, sinus and urinary tract infections and sexually transmitted diseases, may raise or reduce blood sugar to a dangerous level in diabetics, found a new study scheduled to appear in the March 30 issue of the New England Journal of Medicine.
Previous studies have already found that gatifloxacin is associated with both hypoglycemia and hyperglycemia. Compared with macolides, use of gatifloxacin was linked with a 4.3 times higher risk of hypoglycemia and with a 16.7 times higher risk of hyperglycemia. The risk is similarly present among both diabetics and non-diabetics.
Along with gatifloxacin, cephalosporin, levofloxacin, moxifloxacin, or ciprofloxacin were also studied, but no risk was found to be with these antibiotics.
Antibiotics can indiscriminately kill all types of bacteria including those beneficial ones in the intestines, which may flourish growth of other biological species such as toxin-producing molds.